These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 22642877)

  • 41. A small molecule STAT3 inhibitor, LLL12, enhances cisplatin‑ and paclitaxel‑mediated inhibition of cell growth and migration in human ovarian cancer cells.
    Zhang R; Chen X; Fu S; Xu L; Lin J
    Oncol Rep; 2020 Sep; 44(3):1224-1232. PubMed ID: 32705214
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dose-dense cisplatin/paclitaxel. a well-tolerated and highly effective chemotherapeutic regimen in patients with advanced ovarian cancer.
    de Jongh FE; de Wit R; Verweij J; Sparreboom A; van den Bent MJ; Stoter G; van der Burg ME
    Eur J Cancer; 2002 Oct; 38(15):2005-13. PubMed ID: 12376205
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Paclitaxel plus ifosfamide in advanced ovarian cancer: a multicenter phase II study.
    Miglietta L; Amoroso D; Bruzzone M; Granetto C; Catsafados E; Mammoliti S; Guarneri D; Pedulla F; Foglia G; Ragni N; Martini MC; Brema F; Addamo G; Moraglio L; Pastorino G; Boccardo F
    Oncology; 1997; 54(2):102-7. PubMed ID: 9075779
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Current status of chemotherapy for ovarian cancer.
    Ozols RF
    Semin Oncol; 1995 Oct; 22(5 Suppl 12):61-6. PubMed ID: 7481863
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Therapy effect of either paclitaxel or cyclophosphamide combination treatment in patients with epithelial ovarian cancer and relation to TP53 gene status.
    Smith-Sørensen B; Kaern J; Holm R; Dørum A; Tropé C; Børresen-Dale AL
    Br J Cancer; 1998 Aug; 78(3):375-81. PubMed ID: 9703286
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer.
    McGuire WP; Hoskins WJ; Brady MF; Kucera PR; Partridge EE; Look KY; Clarke-Pearson DL; Davidson M
    N Engl J Med; 1996 Jan; 334(1):1-6. PubMed ID: 7494563
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A phase I trial of intravenous melphalan, paclitaxel, and cisplatin plus granulocyte-colony stimulating factor in patients with suboptimal advanced epithelial ovarian carcinoma or peritoneal carcinoma.
    Gershenson DM; Morris M; Burke TW; Levenback C; Wolf J; Lee JJ; Thall PF; Atkinson EN; Silva EG; Wharton JT
    Cancer; 1999 Dec; 86(11):2291-300. PubMed ID: 10590370
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Differential activation of NF-κB signaling is associated with platinum and taxane resistance in MyD88 deficient epithelial ovarian cancer cells.
    Gaikwad SM; Thakur B; Sakpal A; Singh RK; Ray P
    Int J Biochem Cell Biol; 2015 Apr; 61():90-102. PubMed ID: 25681684
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Low-dose naltrexone suppresses ovarian cancer and exhibits enhanced inhibition in combination with cisplatin.
    Donahue RN; McLaughlin PJ; Zagon IS
    Exp Biol Med (Maywood); 2011 Jul; 236(7):883-95. PubMed ID: 21685240
    [TBL] [Abstract][Full Text] [Related]  

  • 50. PG545 enhances anti-cancer activity of chemotherapy in ovarian models and increases surrogate biomarkers such as VEGF in preclinical and clinical plasma samples.
    Winterhoff B; Freyer L; Hammond E; Giri S; Mondal S; Roy D; Teoman A; Mullany SA; Hoffmann R; von Bismarck A; Chien J; Block MS; Millward M; Bampton D; Dredge K; Shridhar V
    Eur J Cancer; 2015 May; 51(7):879-892. PubMed ID: 25754234
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The use of paclitaxel and cisplatin in a patient with epithelial ovarian cancer and human immunodeficiency virus.
    Knox SN; Robinson JB; Im DD; Logan L; Rosenshein NB
    Gynecol Oncol; 2000 Jan; 76(1):118-22. PubMed ID: 10620453
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mifepristone sensitizing cisplatin for cervical adenocarcinoma HeLa cell sensitivity to chemotherapy and its mechanism.
    Li C; Ye H
    Eur J Gynaecol Oncol; 2013; 34(2):142-7. PubMed ID: 23781585
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Synergistic effects of the sesquiterpene lactone, EPD, with cisplatin and paclitaxel in ovarian cancer cells.
    van Haaften C; Boot A; Corver WE; van Eendenburg JD; Trimbos BJ; van Wezel T
    J Exp Clin Cancer Res; 2015 Apr; 34(1):38. PubMed ID: 25907439
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sequence dependence of paclitaxel (Taxol) combined with cisplatin or alkylators in human cancer cells.
    Liebmann JE; Fisher J; Teague D; Cook JA
    Oncol Res; 1994; 6(1):25-31. PubMed ID: 7919549
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Correlation between extreme drug resistance assay and response to primary paclitaxel and cisplatin in patients with epithelial ovarian cancer.
    Eltabbakh GH; Piver MS; Hempling RE; Recio FO; Lele SB; Marchetti DL; Baker TR; Blumenson LE
    Gynecol Oncol; 1998 Sep; 70(3):392-7. PubMed ID: 9790793
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of combination therapy with paclitaxel and cisplatin versus cyclophosphamide and cisplatin in patients with suboptimal stage III and stage IV ovarian cancer: a Gynecologic Oncology Group study.
    McGuire WP; Hoskins WJ; Brady MF; Kucera PR; Partridge EE; Look KY; Clarke-Pearson DL; Davidson M
    Semin Oncol; 1997 Feb; 24(1 Suppl 2):S2-13-S2-16. PubMed ID: 9045329
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Paclitaxel and cisplatin combination chemotherapy in recurrent epithelial ovarian cancer.
    Goldberg JM; Piver MS; Hempling RE; Recio FO
    Gynecol Oncol; 1996 Dec; 63(3):312-7. PubMed ID: 8946864
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Role of salvage chemotherapy with topotecan and cisplatin in patients with paclitaxel- and platinum-resistant recurrent ovarian or primary peritoneal cancer: a phase II pilot study.
    Ghamande SA; Piver MS
    J Surg Oncol; 1999 Nov; 72(3):162-6. PubMed ID: 10562363
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/platinum in European patients with advanced epithelial ovarian cancer.
    van der Burg ME; Onstenk W; Boere IA; Look M; Ottevanger PB; de Gooyer D; Kerkhofs LG; Valster FA; Ruit JB; van Reisen AG; Goey SH; van der Torren AM; ten Bokkel Huinink D; Kok TC; Verweij J; van Doorn HC
    Eur J Cancer; 2014 Oct; 50(15):2592-601. PubMed ID: 25096168
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Latest information in the diagnoses of ovarian carcinoma].
    Isonishi S
    Gan To Kagaku Ryoho; 2002 Aug; 29(8):1351-7. PubMed ID: 12214460
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.